Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Quest Diagnostics beats Q2 estimates; Jefferies raises price target to $245

DGX

$226.00

+$16.17 +7.71%

Quest Diagnostics beats Q2 estimates; Jefferies raises price target to $245

Company Fundamentals

23 Jul 2026

Danny Green

View Source

Bullish

Quest Diagnostics reported strong Q2 results with adjusted EPS of $3.12, a 19.1% increase year-over-year, beating analyst estimates of $2.83. Revenue rose 10.2% to $3.04 billion, driven by a 13.1% increase in test volume, surpassing expectations. Jefferies responded by reaffirming a "Buy" rating and raising the price target from $225 to $245, reflecting confidence in the company's growth. Quest also raised its full-year 2026 revenue and EPS outlook, signaling continued strong demand for its diagnostic services.

More News (DGX)

Quest Diagnostics Q2 revenue rises 10.2%, adjusted EPS up 19.1%, raises full-year guidance

Quest Diagnostics reported a 10.2% increase in second-quarter revenues to $3.04 billion, driven by 10% organic growth. Adjusted diluted earnings per share rose 19.1% to $3.12, reflecting strong demand across physician, hospital, and consumer channels...

Company Fundamentals

Bullish

13 hours ago